MSTRX Performance — Morningstar Total Return Bond Fund, Institutional Class
Data updated: 2026-09-28
MSTRX returned −0.88% year to date and +2.36% over one year to Jul 2026. Annualised returns are +3.38% over 3 years and −1.10% over 5 years. The fund trailed its Moderate Allocation category average: $100 invested three years ago grew to $110, against $134 for the category, and to $102 over one year, against $112. Volatility over the past three years was 5.71% a year. In the 12 months to Jul 2026 the fund took in a net $15.7M, and assets reached $942.87M.
MSTRX Growth of $100
What $100 invested in Morningstar Total Return Bond Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Moderate Allocation category average over the same months.
| Period | MSTRX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $102 | $112 |
| 3 years (Aug 2023 – Jul 2026) | $110 | $134 |
| 5 years (Aug 2021 – Jul 2026) | $95 | $129 |
| Since data start (Feb 2020 – Jul 2026) | $101 | $149 |
MSTRX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | −0.88% |
| 1 year | +2.36% |
| 3 years (annualised) | +3.38% |
| 5 years (annualised) | −1.10% |
MSTRX Annual Returns
Calendar-year total returns of Morningstar Total Return Bond Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | −0.88% |
| 2025 | +6.22% |
| 2024 | +1.74% |
| 2023 | +5.55% |
| 2022 | −15.54% |
| 2021 | −1.55% |
| 2020 (Feb–Dec) | +7.55% |
MSTRX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.2% | +1.5% | −2.0% | +0.1% | +0.3% | +0.4% | −1.3% | — | — | — | — | — |
| 2025 | −0.2% | +2.1% | 0.0% | +0.2% | −0.7% | +1.5% | −0.2% | +1.1% | +1.1% | +0.6% | +0.5% | −0.1% |
| 2024 | −0.2% | −1.4% | +0.9% | −2.5% | +1.7% | +0.9% | +2.4% | +1.5% | +1.3% | −2.7% | +1.1% | −1.0% |
| 2023 | +3.5% | −2.6% | +2.6% | +0.6% | −1.2% | −0.3% | −0.2% | −0.7% | −2.8% | −1.7% | +4.6% | +3.9% |
| 2022 | −2.5% | −1.7% | −3.2% | −4.3% | +0.6% | −2.1% | +2.7% | −2.9% | −5.0% | −1.6% | +4.0% | −0.3% |
| 2021 | −0.9% | −1.9% | −1.1% | +1.0% | +0.2% | +1.0% | +1.1% | −0.1% | −0.9% | −0.1% | +0.2% | −0.1% |
| 2020 | — | +1.3% | −2.9% | +3.2% | +1.5% | +1.3% | +2.1% | −0.5% | −0.1% | −0.4% | +1.6% | +0.4% |
MSTRX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 5.71%
- 3-year Sharpe ratio: -0.20 (vs 4.5% risk-free rate)
- Best month: +4.64% (Nov 2023)
- Worst month: −2.79% (Sep 2023)
MSTRX Fund Flows
Monthly money in and out of Morningstar Total Return Bond Fund, from SEC Form N-PORT.
- 12-month net flow: $15.7M
- 12-month gross sales (incl. reinvestments): $228.9M
- Sales ÷ redemptions: 1.07×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $23.1M | $19.1M | $4.0M |
| Jun 2026 | $17.1M | $20.5M | −$3.4M |
| May 2026 | $23.6M | $15.5M | $8.1M |
| Apr 2026 | $28.3M | $23.6M | $4.7M |
| Mar 2026 | $14.8M | $19.4M | −$4.6M |
| Feb 2026 | $13.0M | $13.1M | −$99K |
| Jan 2026 | $18.2M | $17.0M | $1.2M |
| Dec 2025 | $23.7M | $15.9M | $7.8M |
| Nov 2025 | $12.7M | $18.5M | −$5.9M |
| Oct 2025 | $17.3M | $16.9M | $405K |
| Sep 2025 | $24.8M | $16.7M | $8.0M |
| Aug 2025 | $12.4M | $17.1M | −$4.7M |
MSTRX Assets Under Management
Net assets of Morningstar Total Return Bond Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $942.87M |
| 2026-04-30 | $951.30M |
| 2026-01-30 | $963.44M |
| 2025-10-31 | $964.90M |
| 2025-07-31 | $943.65M |
| 2025-04-30 | $874.52M |
| 2025-01-31 | $895.65M |
| 2024-10-31 | $869.51M |
| 2024-07-31 | $871.54M |
| 2024-04-30 | $820.13M |
| 2024-01-31 | $846.56M |
| 2023-10-31 | $752.97M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.